Longeveron LLC, a Miami-based company developing allogeneic mesenchymal stem cell therapies (MSCs) for aging-related conditions, has landed a $750,000 grant from the Maryland Technology Development Corp. to support an ongoing trial examining the safety and efficacy of its bone-marrow-sourced cells to improve flu vaccine immune-response in elderly patients with aging frailty.
